These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 12243977)

  • 1. Treatment of lymphoid malignancies with non-myeloablative stem cell transplantation.
    Seftel MD; Lavoie J; Barnett MJ; Conneally E
    Hematology; 2002 Jun; 7(3):151-5. PubMed ID: 12243977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.
    Atilla E; Ataca Atilla P; Demirer T
    Balkan Med J; 2017 Jan; 34(1):1-9. PubMed ID: 28251017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
    Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies].
    Hansz J
    Pol Arch Med Wewn; 2001; 105 Suppl():173-5. PubMed ID: 12412244
    [No Abstract]   [Full Text] [Related]  

  • 10. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.
    Goldstein SC; Porter DL
    Expert Rev Hematol; 2010 Jun; 3(3):301-14. PubMed ID: 21082981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Allogeneic hematopoietic stem cell transplantation in elderly].
    Castagna L; Blaise D; Furst S
    Bull Cancer; 2011 Aug; 98(8):915-25. PubMed ID: 21835732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ten years of changes in conditioning regimen for allogenic hematopoietic stem cell transplantation in adults].
    Peffault de Latour R; Cabrespine-Faugeras A; Bay JO
    Bull Cancer; 2008 Jan; 95(1):87-97. PubMed ID: 18230574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect.
    Gill S; Porter DL
    Annu Rev Med; 2013; 64():101-17. PubMed ID: 23121181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical review on non-myeloablative stem cell transplantation (NST).
    Anagnostopoulos A; Giralt S
    Crit Rev Oncol Hematol; 2002 Nov; 44(2):175-90. PubMed ID: 12413634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
    Morecki S; Gelfand Y; Nagler A; Or R; Naparstek E; Varadi G; Engelhard D; Akerstein A; Slavin S
    Bone Marrow Transplant; 2001 Aug; 28(3):243-9. PubMed ID: 11535991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy].
    Hagihara M; Kanamori H; Sakai M; Mori T; Nakaseko C; Aotsuka N; Uehara T; Sakura T; Yoshiba F; Kawai N; Tanaka M; Fujisawa S; Ohwada C; Wakita H; Yokota A; Kawamura T; Maruta A; Sakamaki H; Okamoto S;
    Rinsho Ketsueki; 2010 Jun; 51(6):390-7. PubMed ID: 20622484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():176-83. PubMed ID: 12430850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.